nav search

R&D of cancer drugs underway at Tangjiawan facility


Updated: 2019-08-15

Biotheus commenced R&D operations Aug 13 at a new 4,200-sq-m (1-acre) center in Tangjiawan seeking effective therapeutic biologics for patients with cancer and metabolic diseases.

The bio-tech startup, founded in 2018, is headquartered in CEC High-Tech Industrial Park of the Zhuhai National Hi-Tech Industrial Development Zone in Tangjiawan. Biotheus develops innovative antibody drugs in concert with laboratories in Hong Kong and Suzhou. It seeks to lead China's biomedical sector in the Guangdong-Hong Kong-Macao Greater Bay Area, according to CEO Liu Xiaolin.

Although the company is new, Biotheus teams have an average of 15 years' experience in research, development, and industrialization of high-end biologic drugs. They have engaged in the R&D of over 40 new drugs, and the company's products have generated more than $20 billion in sales.


Drug test [File photo]

Biotheus completed Pre-A round financing of more than 100 million yuan ($14 million) in June, its second round of financing after a 180-million-yuan ($25.7-million) investment by Zhuhai Huajin Capital, Zhuhai Hi-Tech VC, and Jiangsu-based Highlight Capital.

Currently, it is focusing on independent R&D of new-generation bi-specific antibody drugs and a dozen national first-class new biologic drugs to treat malignant tumors and metabolic diseases. Its annual operating revenue is expected to exceed 3 billion yuan ($427.6 million) by 2023.



Promising bio-tech firm looking for new breakthrough

Prometheus Bio-technology will develop innovative biomedical projects valued at 800 million yuan ($125 million) in Zhuhai with revenue expected to exceed 3 billion yuan ($469 million) once production begins.

Join in

1.jpg Sculpture exhibition sheds light on people's life in the GBA

Piquing Interest

640.webp.jpg Radiant fields of lavender myrtle blossom in Pingsha

Living Here

1.jpg Now 'on solid ground,' Zhuhai Airport serves millions
Copyright © Zhuhai Municipal Government. All rights reserved. Presented by China Daily